Aprea Therapeutics (APRE) announced that preliminary safety results on its WEE1 inhibitor APR-1051 are highlighted in a poster being presented today at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place in Barcelona, Spain. Data are available on two of three patients, with a cutoff date of October 7, 2024: Preliminary results demonstrate that APR-1051 is safe and well-tolerated with no hematologic toxicity; Hemoglobin, hematocrit, and platelet counts were stable or increased slightly during the first treatment cycle; There were no signs of neutropenia, with white blood cells and neutrophils trending up for both patients during the first treatment cycle; All adverse events recorded were Grade 1 and 2, with one Grade 1 AE possibly related to APR-1051; No QT prolongation has been observed; Three patients have been dosed to date with data available on two of these. One had disease progression at 49 days, a second withdrew following 36 days of treatment and dosing is ongoing in the third patient.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on APRE:
- Biotech Alert: Searches spiking for these stocks today
- Aprea Therapeutics engages Philippe Pultar as senior medical advisor
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
